Alkem Laboratories Limited (ALKEM.NS)
Company Info
Highlights
₹591.43B
₹180.18
27.45
₹98.21B
₹56.53B
₹24.69B
₹4,368.53 - ₹6,389.41
₹5,365.71
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Alkem Laboratories Limited (ALKEM.NS) returned -11.51% year-to-date (YTD) and -2.71% over the past 12 months.
ALKEM.NS
-11.51%
2.22%
-12.63%
-2.71%
14.96%
N/A
^GSPC (Benchmark)
-3.77%
7.44%
-5.60%
8.37%
14.12%
10.46%
Monthly Returns
The table below presents the monthly returns of ALKEM.NS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -9.42% | -8.23% | 5.07% | 4.80% | -3.31% | -11.51% | |||||||
| 2024 | -3.97% | 3.31% | -3.61% | -2.20% | -0.47% | 3.76% | 6.37% | 16.32% | -1.91% | -4.52% | -2.37% | -0.15% | 9.11% |
| 2023 | 0.22% | 5.92% | 6.96% | 3.35% | -4.28% | 4.56% | 13.26% | -8.22% | -1.01% | 3.22% | 26.91% | 10.14% | 74.36% |
| 2022 | -2.34% | -6.58% | 10.46% | -10.23% | -3.12% | -4.78% | 7.56% | -7.65% | 10.17% | -3.72% | -0.98% | -3.82% | -16.27% |
| 2021 | 2.76% | -8.68% | 1.75% | -0.39% | 8.34% | 7.03% | 7.95% | 12.47% | 2.63% | -9.30% | -0.48% | 0.85% | 25.11% |
| 2020 | 19.06% | 10.42% | -11.41% | 11.76% | -12.95% | 4.66% | 12.41% | 2.38% | 2.03% | -5.17% | 7.87% | 2.98% | 46.67% |
| 2019 | -3.39% | -6.99% | -0.12% | -1.34% | 4.42% | -6.99% | 4.37% | 4.82% | 4.81% | 4.86% | 1.57% | -0.75% | 4.25% |
| 2018 | -0.14% | 1.54% | -10.69% | -0.60% | -3.01% | -1.34% | 12.05% | 0.13% | -2.83% | -7.21% | 0.30% | 1.91% | -10.93% |
| 2017 | 2.44% | 28.36% | 2.96% | -10.59% | -2.02% | -3.93% | -1.27% | -1.23% | 2.24% | 1.80% | 6.05% | 10.81% | 35.89% |
| 2016 | -8.51% | -6.93% | 8.03% | -12.20% | 6.08% | 9.58% | 13.17% | -1.21% | 7.33% | -1.77% | 4.54% | -4.19% | 10.84% |
| 2015 | 7.49% | 7.49% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ALKEM.NS is 43, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Alkem Laboratories Limited (ALKEM.NS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Alkem Laboratories Limited provided a 0.85% dividend yield over the last twelve months, with an annual payout of ₹42.00 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | ₹42.00 | ₹40.00 | ₹25.00 | ₹34.00 | ₹30.00 | ₹25.00 | ₹16.00 | ₹13.00 | ₹9.00 | ₹15.70 |
Dividend yield | 0.85% | 0.71% | 0.48% | 1.13% | 0.83% | 0.85% | 0.79% | 0.67% | 0.41% | 0.96% |
Monthly Dividends
The table displays the monthly dividend distributions for Alkem Laboratories Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₹0.00 | ₹37.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹37.00 | |||||||
| 2024 | ₹0.00 | ₹35.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹5.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹40.00 |
| 2023 | ₹0.00 | ₹15.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹10.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹25.00 |
| 2022 | ₹0.00 | ₹30.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹4.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹34.00 |
| 2021 | ₹0.00 | ₹25.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹5.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹30.00 |
| 2020 | ₹0.00 | ₹22.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹3.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹25.00 |
| 2019 | ₹0.00 | ₹8.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹8.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹16.00 |
| 2018 | ₹0.00 | ₹6.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹7.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹13.00 |
| 2017 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹9.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹9.00 |
| 2016 | ₹9.70 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹6.00 | ₹0.00 | ₹15.70 |
Dividend Yield & Payout
Dividend Yield
Alkem Laboratories Limited has a dividend yield of 0.85%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
Alkem Laboratories Limited has a payout ratio of 26.81%, which is quite average when compared to the overall market. This suggests that Alkem Laboratories Limited strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Alkem Laboratories Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alkem Laboratories Limited was 27.75%, occurring on Feb 25, 2025. The portfolio has not yet recovered.
The current Alkem Laboratories Limited drawdown is 21.69%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -27.75% | Sep 16, 2024 | 115 | Feb 25, 2025 | — | — | — |
| -27.4% | Jan 11, 2018 | 358 | Jun 28, 2019 | 132 | Jan 13, 2020 | 490 |
| -26.86% | Sep 27, 2021 | 158 | May 17, 2022 | 296 | Jul 25, 2023 | 454 |
| -23.77% | Jan 6, 2016 | 86 | May 13, 2016 | 49 | Jul 22, 2016 | 135 |
| -22.86% | Mar 28, 2017 | 95 | Aug 11, 2017 | 95 | Dec 29, 2017 | 190 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Alkem Laboratories Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Alkem Laboratories Limited, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 2.4% positive surprise.
Valuation
The Valuation section provides an overview of how Alkem Laboratories Limited is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ALKEM.NS, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ALKEM.NS has a P/E ratio of 27.5. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ALKEM.NS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ALKEM.NS has a P/S ratio of 4.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ALKEM.NS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ALKEM.NS has a P/B value of 5.1. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |